Redeye is encouraged to see AroCell recording its first quarter with a positive cash flow, and the report solidifies our take on the coming quarters. We learn about a coming strategic overview that could entail an acquisition, but nothing concrete has been announced. We leave our base case intact and point to AroCell trading at undeservedly low EV/sales multiples.